Table 3 rPDDI before start of cancer therapy (n = 136) and after start of cancer therapy (n = 128)
Type of interaction | Number of interactions | ABDA database classification | Mechanism/effect of interaction |
|---|---|---|---|
Interactions before start of cancer therapy | |||
Anti-diabetic drugs – corticosteroids | 8 | Monitoring/modification needed | Hyperglycemic effect of corticosteroids |
Agents acting on the renin-angiotensin system – heparinoids | 8 | Monitoring/modification needed | Increased risk of hyperkalemia |
Simvastatin – amlodipine | 8 | Monitoring/modification needed | Amlodipine inhibits simvastatin metabolism via CYP3A4 leading to higher risk of myopathy |
Beta agonists – beta blocker | 6 | Monitoring/modification needed | Antagonistic effects |
ACE inhibitors – allopurinol | 5 | Monitoring/modification needed | Increased risk of immunologic reactions (mechanism unknown) |
Amiodarone – beta blockers | 4 | Monitoring/modification needed | Additive cardio depressive effects |
Thyroid hormones – polyvalent cations | 4 | Monitoring/modification needed | Decreased effect of thyroid hormones due to reduced resorption |
Insulins – cardio selective beta blockers | 3 | Monitoring/modification needed | Increased risk of hypoglycemia, masking of hypoglycemic symptoms |
NSAIDs – corticosteroids | 3 | Monitoring/modification needed | Higher risk of gastrointestinal ulcer |
Thiazide-diuretics – vitamin D | 3 | Monitoring/modification needed | Higher risk of hypercalcemia |
Others | 19 | Various | Various |
Interactions after start of cancer therapy | |||
NSAIDs – corticosteroids | 8 | Monitoring/modification needed | Higher risk of gastrointestinal ulcer |
Cytotoxic agents – thiazide diuretics | 7 | Monitoring/modification needed | Increased myelosuppressive effects |
Anti-diabetic drugs – corticosteroids | 5 | Monitoring/modification needed | Hyperglycemic effect of corticosteroids |
ACE inhibitors – allopurinol | 4 | Monitoring/modification needed | Increased risk of immunological reactions (mechanism unknown) |
Hyperkalemic drugs – trimethoprim | 4 | Monitoring/modification needed | Increased risk of hyperkalemia due to additive effects on potassium levels |
QT prolonging drugs – antidepressant | 3 | Simultaneous usage not recommended | Increased risk of torsades de pointes |
QT prolonging drugs – antiarrhythmic agent | 3 | Serious consequences possible – as precaution contraindicated | Increased risk of torsades de pointes |
Loop diuretics – platinum compounds | 3 | Monitoring/modification needed | Higher risk of nephrotoxicity/ototoxicity |
Nitrogen mustard derivatives – allopurinol | 3 | Monitoring/modification needed | Additive myelotoxic effects |
Fluoropyrimidines – folate a | 2 | Monitoring/modification needed | Higher toxicity of fluoropyrimidines |
Others | 8 | Various | Various |